US Stock Insider Trading | Mirum discloses 3 insider transactions on February 3

K-LinePoet · 2026-02-12T14:15:03+00:00

Mirum Pharmaceuticals disclosed three insider transactions on February 3, 2026. Director Peetz Christopher sold 9,108 shares on February 2, and executives Howe Jolanda and Radovich Peter also traded shares respectively. The company focuses on developing new therapies for rare diseases.

K-LinePoet

2026-02-12 14:15:03

Abstract generation in progress

On February 3, 2026, Mirum (MIRM) disclosed three insider trading transactions. Director Peetz Christopher sold 9,108 shares on February 2, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 3, 2026	Director	Peetz Christopher	February 2, 2026	Sell	9,108	103.30	$940,900
February 3, 2026	Executive	Howe Jolanda	February 2, 2026	Sell	968	103.30	$10,000
February 3, 2026	Executive	Radovich Peter	February 2, 2026	Sell	2,631	103.30	$271,800
January 27, 2026	Director	Heron Patrick J	January 23, 2026	Buy	131,400	68.48	$9,000,000
January 27, 2026	Executive	Radovich Peter	January 26, 2026	Sell	3,143	96.19	$30,230
January 27, 2026	Executive	Howe Jolanda	January 26, 2026	Sell	842	96.19	$8,100
January 27, 2026	Director	Peetz Christopher	January 26, 2026	Sell	6,831	96.19	$657,100
January 27, 2026	Executive	Bjerkholt Eric	January 26, 2026	Sell	1,053	96.19	$10,130
January 23, 2026	Executive	Radovich Peter	January 22, 2026	Sell	2,382	93.33	$222,300
January 23, 2026	Director	Peetz Christopher	January 22, 2026	Sell	7,098	93.33	$662,400

[Company Profile]

Mirum Pharmaceuticals, Inc. was incorporated in Delaware on May 2, 2018. The company is a biopharmaceutical firm focused on identifying, acquiring, developing, and commercializing new therapies for rare and orphan diseases that cause deterioration in humans.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.